UBS Group
CGTX icon

UBS Group’s Cognition Therapeutics CGTX Stock Holding History

UBS Group’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$251K Buy
218,536
+141,663
+184% +$168K ﹤0.01% 6666
2026
Q1 		$58.3K Buy
76,873
+2,541
+3% +$2.96K ﹤0.01% 7279
2025
Q4 		$100K Buy
74,332
+8,293
+13% +$13.5K ﹤0.01% 6909
2025
Q3 		$89.2K Buy
66,039
+54,784
+487% +$74.7K ﹤0.01% 7203
2025
Q2 		$3.49K Buy
11,255
+11,254
+1,125,400% +$3.8K ﹤0.01% 9349
2025
Q1 		$0 Sell
1
-41,111
-100% -$24.2K ﹤0.01% 10270
2024
Q4 		$28.8K Sell
41,112
-156,747
-79% -$77.5K ﹤0.01% 7635
2024
Q3 		$92.8K Buy
+197,859
New +$204K ﹤0.01% 6424
2023
Q3 		– Sell
-610
Closed -$1.12K – 9513
2023
Q2 		$1.12K Buy
+610
New +$1.29K ﹤0.01% 8009
2023
Q1 		– Sell
-5,543
Closed -$11.6K – 9661
2022
Q4 		$11.6K Buy
5,543
+2,358
+74% +$4.76K ﹤0.01% 8373
2022
Q3 		$6K Buy
3,185
+2,286
+254% +$4.76K ﹤0.01% 9008
2022
Q2 		$2K Sell
899
-2,850
-76% -$7.36K ﹤0.01% 9517
2022
Q1 		$10K Hold
3,749
– – ﹤0.01% 8398
2021
Q4 		$24K Buy
+3,749
New +$36.6K ﹤0.01% 7622

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

UBS Group's CGTX Position: Q2 2026 in Review

UBS Group increased its Cognition Therapeutics (CGTX) stake by 184% in Q2 2026, buying an estimated $168K and bringing the position to 218,536 shares worth $251K. The position accounts for ﹤0.01% of the portfolio, ranked #6666.

UBS Group first reported a position in CGTX in Q4 2021 and has held it in 14 quarters since. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • UBS Group held 218,536 shares of Cognition Therapeutics worth $251K as of Q2 2026.
  • UBS Group bought 141,663 Cognition Therapeutics shares in Q2 2026, an estimated $168K.
  • Cognition Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6666 holding.
  • UBS Group first reported a position in Cognition Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.